Background: Hepatitis C virus infection (HCV) is a global health problem which develops chronic hepatic diseases including liver cirrhosis and hepatocellular carcinoma. IL28B polymorphisms rs12979860 CC genotype and low serum level of interleukin10 were associated to protect the patients of HCV infection and rapid virological response (RVR) in HCV patients treated for four weeks with pegIFNα/ribavirin (IFNα/RIB). Subjects and methods: The study was carried out on 49 Egyptian HCV patients, Patients with other types of viral hepatitis, unfavourable haematological picture & decompensated liver function including cirrhosis and Autoimmune hepatitis were excluded. Patients who responsing to IFNα/RIB after four weeks were classified as RVR (n = 18) and Non-RVR (n = 31). IL28B polymorphisms at rs12979860, the resulting genotypes are CC, CT or TT, and Serum IL10 was measured by standard sandwich enzyme-linked immune-sorbent assay technology for both groups. Results: Il28B CC genotype was 67.4 % in responder group (RVR) 38.7% in non-responder group (non RVR) (p= 0.01), CC genotype with serum IL10 < 80 pg/mL was 72.2% in responder group and CT/TT with serum IL10 >80 pg/mL (p= 0.00). Conclusion: the relationship of genotype CC of IL28B at rs12979869 and the effect of IFNα/RIB to maintain the serum level of IL10 decrease and to achieve better chances to cure the HCV patients from the virus.
INTRODUCTION
epatitis C virus infection (HCV) is a global health problem which develops chronic hepatic diseases including liver cirrhosis and hepatocellular carcinoma (HCC) [1] . The treatment regimen for HCV Patients infection is subcutaneous injections of long acting pegylated interferon α (PEG -IFN) and oral ribavirin (RIB). This treatment give a sustained virological response (SVR) in only 40-50% of HCV patients [2] . Interleukin -10 (IL -10) is an immunoregulatory cytokinereleased by B lymphocytes, macrophages and dendritic cells, and due to its immunoregulatory action, the inadequate levels of IL-10 can determine escaping of virus from immune system and give rise to persistent infections.
High levels of serum IL-10 have been related with poor response to interferon therapy [3] . IL -28 is a cytokine that plays a role in immune defence against viruses, IL-28 B polymorphism in HCV patients was found to be correlated with HCV treatment response with decrease in RNA after 4 weeks and considered as one of the most important predictor of treatment response [4] . This relation of single nucleotide polymorphism in IL -28B gene region with pegylated interferon treatment outcome raises the possibility of using IL-28B (interferon lambda) as a therapeutic agent against hepatitis C [5] . The serum level of IL10 in response to the HCV therapy and the IL28B genotype are the H Abousreaa A.; et al…..
-632-most predictive coacting immunological factors in clearance from HCV infection. [3] . samples were collected and kept at _20 _C for 24 h until extraction of DNA. DNA quantitation and purity analysiss was done by using Nanodrop 2000 spectrophotometer (Thermo Scientific, USA). Then PCR-detection of gene polymorphism of IL28B was done.
SUBJECTS AND METHODS

Serum levels quantification of IL10
Using standard sandwich enzyme-linked immune-sorbent assay technology. An IL-10 specific monoclonal antibody extracted from mice coating 96-well plates. Then serial dilution of Standards and study samples were added to the wells, a biotinylated detection IL-10 specific polyclonal antibody was added subsequently and washing using the washing buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with washing buffer. Then HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalysed by HRP and producing a blue colour which turned to yellow after addition of stop solution. Then microplate reader can read the O.D. absorbance at 450nm within 30 min after the stop solution added [6] . .00* DISCUSSION In our study rs1297860 genotype CC of IL28B was found to be significantly associated with a positive response to PEG-IFN-α and RBV in HCV patients with genotype 4 among Egyptian patients than the other genotypes. Other study showed that the rs12979860 polymorphism was likely to be associated with natural clearance [7] . As such, it seems likely Abousreaa A.; et al…..
STATISTICAL ANALYSIS
-635-that the rs12979860 variation could be involved in the innate immune response to HCV. Some other variations in IL28B, such as rs8099917, rs12980275, rs8105790, rs11881222, rs8103142, rs28416813, rs4803219 and rs7248668, have been reported to be associated with the outcomes of anti-HCV treatment [8] . A highly significant correlation between RVR and treatment was observed with the genotypes rs12979860 CC, rs8099917 TT, and rs12980275 AA. Our thesis was concentrated on the possible association between serum level of IL-10 and HCV patient treatment response. In this study, there is a significant positive correlation between pre-treatment IL-10 serum level and (BMI), in agreement with Reuss et al. also there is a significant positive correlation between pretreatment IL-10 serum level and viral load in agreement with Flynn et al. [9] . our study showed that there were no correlation between seum level of IL-10 and the stage of fibrosis in agreement with Imbert-Bismut et al. [10] , who showed that IL-10 serum level had no relation to the stage of fibrosis Also, we noticed that serum level of IL-10 was significantly low in responders (116.7±5.6) compared to nonresponders (138.7±13.4), in agreement with Marín-Serrano et al. [11] . In our study we found that there is a correlation of IL28B genotype and serum level of IL10 and the outcome and response of treatment of chronic HCV patients, and to understand this correlation the measurement of serum level of IL-10 at the beginning of treatment (after 4 weeks) in the patients classified by IL28B genotype into CC and CT/TT. In agree with Umemura et al. who used the same approach to study the effect of the minor allele G from IL28B with different polymorphism at rs8099917 measuring the serum level of IL10 before treatment. [3] . IN our study the obtained results showed that there were possible co-acting effect of decreased serum level of IL10 and the IL28B genotypes related to RVR in the therapy of HCV patients. In this thesis, the responders carrying IL28B CC genotype compared to CT/TT genotypes showed low serum levels of IL-10, suggesting that this decrease in serum levels of IL-10 may be due to IFN-a/RIB therapy and can be high level in CC genotype (p = 0.02), which responds to therapy. [7] . Finally the predicted CC genotype patients produce serum levels of IL10 <80 pg/ml and have more possibility to be cured from the virus and achieve RVR. than patients with other CT/TT genotype and IL10 serum level < 80 pg/ml, and the statistical analysis was done in the study confirmed that observation with a lowest possibility of patients with CT/TT genotypes and serum level of IL10 < 80 pg/ml to achieve RVR. So that we must consider all discussed variables for calculation of a supposed negative predictive value to expect the CT/TT failure which considered as an important data to guide the physicians to start and select the suitable clinical management [12] . CONCLUSION IL28 b polymorphism and pretreatment serum level IL-10 are significantly associated factors with the response of the treatment in Egyptian patients with HCV infection of genotype 4 as higher serum level of IL-10 is a poor prognostic marker for treatment response., HCV genotyping, and also serum IL-10 and IL28B gene must done before treatment as these variables considered as an important factors which decide we will or will not start the treatmentand also will be cost sffective and reduce side effects of treatment. 
